医学
贝伐单抗
乳腺癌
肿瘤科
转移
入射(几何)
曲妥珠单抗
转移性乳腺癌
内科学
脑转移
全身疗法
不利影响
靶向治疗
化疗
癌症
CA15-3号
炎症性乳腺癌
鞘内
脑膜癌病
外科
放射科
总体生存率
放射治疗
临床试验
生物制剂
作者
Junmei Zhang,Xuezheng Wang,Tiezhu Li,Luyao Yang,Yan Xue
标识
DOI:10.3389/fonc.2026.1961848
摘要
Leptomeningeal metastasis from breast cancer has a low incidence but an extremely poor prognosis. With the development of antitumor therapies, the survival of patients with metastatic breast cancer has been significantly prolonged. However, due to the presence of the blood-brain barrier, intracranial metastasis has become increasingly prominent, and the incidence of leptomeningeal metastasis is gradually rising, warranting greater attention and improvement. Currently, there is a lack of effective treatment options for leptomeningeal metastasis, and no unified diagnostic or therapeutic standards exist. This case series reports seven breast cancer patients with leptomeningeal metastasis who received trastuzumab deruxtecan combined with whole-brain radiotherapy; four of them also received bevacizumab and intrathecal chemotherapy. In these four patients, the addition of bevacizumab and intrathecal therapy was associated with rapid alleviation of central nervous system symptoms and a numerically longer overall survival (9.0-20.2 months) compared with historical data. No severe or fatal adverse events were observed. Additionally, through a review of the literature, we summarize the current status, diagnosis, treatment, prognosis, and potential future directions of leptomeningeal metastasis from breast cancer, aiming to provide reference for the management of these patients.
科研通智能强力驱动
Strongly Powered by AbleSci AI